Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 27, 2012BloodOpen Access

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSuzanne LentzschColumbia University Irving Medical CenterAOAmy K. O’SullivanEADA Business SchoolRKRyan KennedyBroad Institute

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lentzsch et al. (2012) studied this question.

synapsesocial.com/papers/6a0fe43cb6f5ee0401601049https://doi.org/10.1182/blood-2011-12-395715
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma2008 · 17 citations
  2. 2Improved survival in multiple myeloma and the impact of novel therapies2007 · 2,265 citations
  3. 3Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 12011 · 1,047 citations
  4. 4Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide2011 · 606 citations
  5. 5Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma2007 · 44 citations